Take Solutions Ltd

Take Solutions Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Take Solutions Ltd

₹ 24.9 4.92%
24 Oct - close price
takesolutions.com BSE: 532890 NSE: TAKE
About

Incorporated in 2000, TAKE Solutions Ltd is in the business of Life Sciences and Support Services[1]

Key Points

Business Overview:[1]
Singapore-based TAKE Solutions Pte Limited holds a 52.90% stake in TSL, serving as the holding company. TSL specializes in Life Sciences and Supply Chain Management, providing comprehensive services in clinical development and specific offerings in supply chain. The company is involved in clinical trials, generics support, including bio-availability & bioequivalent studies, regulatory filing, and pharmacovigilance.

Website BSE NSE
  • Market Cap ₹ 369 Cr.
  • Current Price ₹ 24.9
  • High / Low ₹ 25.0 / 6.51
  • Stock P/E 44.2
  • Book Value ₹ 1.74
  • Dividend Yield 0.00 %
  • ROCE 18.0 %
  • ROE 16.7 %
  • Face Value ₹ 1.00
Edit ratios

Pros

  • Company is almost debt free.

Cons

  • Stock is trading at 14.3 times its book value
  • The company has delivered a poor sales growth of -18.3% over past five years.
  • Company has a low return on equity of -22.8% over last 3 years.
  • Working capital days have increased from 1,495 days to 5,406 days

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Healthcare Healthcare Healthcare Services Healthcare Research, Analytics & Technology

Edit Columns
Loading peers table ...

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025
12.75 16.78 12.75 14.79 5.42 0.00 0.00 0.00 0.90 0.00 0.00 0.00 0.00
15.22 14.27 13.46 12.08 4.41 1.08 1.51 7.94 0.61 0.90 0.76 0.70 2.02
Operating Profit -2.47 2.51 -0.71 2.71 1.01 -1.08 -1.51 -7.94 0.29 -0.90 -0.76 -0.70 -2.02
OPM % -19.37% 14.96% -5.57% 18.32% 18.63% 32.22%
1.24 -0.13 1.24 2.05 -0.34 0.13 0.71 -192.77 -47.94 -26.56 1.93 5.69 0.01
Interest 0.06 0.05 0.04 0.47 0.21 0.19 0.17 0.17 0.16 0.16 0.22 0.20 0.15
Depreciation 0.29 0.28 0.28 0.28 0.30 0.30 0.11 0.01 0.01 0.01 0.01 0.01 0.00
Profit before tax -1.58 2.05 0.21 4.01 0.16 -1.44 -1.08 -200.89 -47.82 -27.63 0.94 4.78 -2.16
Tax % 0.00% 19.02% 66.67% -2.74% 112.50% -24.31% 331.48% 0.30% 0.13% -0.22% 0.00% 0.00% 0.00%
-1.58 1.66 0.08 4.12 -0.02 -1.10 -4.65 -201.49 -47.88 -27.57 0.94 4.78 -2.17
EPS in Rs -0.11 0.11 0.01 0.28 -0.00 -0.07 -0.31 -13.62 -3.24 -1.86 0.06 0.32 -0.15
Raw PDF
Upcoming result date: 27 October 2025

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 TTM
26 26 24 19 2 22 2 11 18 56 5 1 0
22 24 18 22 19 36 19 18 31 53 15 3 4
Operating Profit 4 1 5 -4 -16 -14 -17 -7 -13 3 -10 -2 -4
OPM % 14% 6% 22% -19% -664% -63% -685% -64% -74% 5% -176% -228%
22 13 16 22 33 34 26 15 -460 4 -192 -67 -19
Interest 2 0 0 3 1 0 0 0 0 1 1 1 1
Depreciation 5 1 0 1 1 1 2 2 1 1 1 0 0
Profit before tax 18 13 20 15 15 20 7 7 -475 5 -203 -70 -24
Tax % 5% 15% 10% 1% -3% 11% -11% -20% 0% 9% 2% 0%
17 11 18 14 15 17 8 8 -477 4 -207 -70 -24
EPS in Rs 1.40 0.92 1.49 1.08 1.03 1.18 0.52 0.53 -32.26 0.29 -14.01 -4.71 -1.63
Dividend Payout % 70% 106% 66% 92% 155% 85% 0% 0% 0% 0% 0% 0%
Compounded Sales Growth
10 Years: -29%
5 Years: -18%
3 Years: -63%
TTM: -100%
Compounded Profit Growth
10 Years: -1%
5 Years: 6%
3 Years: 26%
TTM: 130%
Stock Price CAGR
10 Years: -18%
5 Years: -10%
3 Years: 1%
1 Year: 42%
Return on Equity
10 Years: -11%
5 Years: -32%
3 Years: -23%
Last Year: 17%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Equity Capital 12 12 12 13 15 15 15 15 15 15 15 15
Reserves 308 304 307 505 755 748 751 760 284 288 81 11
0 0 73 0 0 0 4 0 2 2 0 0
11 9 22 16 7 12 7 11 11 14 24 6
Total Liabilities 331 325 414 534 777 774 776 786 312 319 119 32
2 1 0 5 4 3 6 4 3 2 0 0
CWIP 0 0 2 0 0 0 0 0 0 0 0 0
Investments 284 234 330 360 414 512 517 517 155 243 102 0
45 90 81 170 359 259 253 265 154 74 17 32
Total Assets 331 325 414 534 777 774 776 786 312 319 119 32

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
37 -3 -11 -33 -24 13 -15 -3 33 27 -4 -20
-19 55 -92 -24 -88 -112 22 13 -40 -22 -1 22
-23 -12 61 58 239 -28 -8 -0 -1 -1 -0 -0
Net Cash Flow -5 41 -42 1 127 -127 -1 11 -9 4 -6 3

Ratios

Standalone Figures in Rs. Crores / View Consolidated

Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Debtor Days 36 43 58 62 136 107 1,034 81 87 0 0 0
Inventory Days
Days Payable
Cash Conversion Cycle 36 43 58 62 136 107 1,034 81 87 0 0 0
Working Capital Days 303 394 -732 1,958 26,943 3,456 33,992 7,839 1,844 242 -1,163 5,406
ROCE % 6% 4% 4% 4% 2% 2% 1% -1% 0% 4% -5% 18%

Shareholding Pattern

Numbers in percentages

8 Recently
Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025
53.41% 53.41% 53.41% 53.41% 53.41% 53.41% 53.41% 53.41% 53.41% 53.41% 53.34% 5.19%
0.13% 0.13% 0.13% 0.00% 0.00% 0.02% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.01% 0.00% 0.00%
46.44% 46.45% 46.46% 46.57% 46.59% 46.56% 46.58% 46.58% 46.59% 46.58% 46.65% 94.81%
No. of Shareholders 86,92483,95082,04581,18379,33681,93880,28878,03377,16375,98875,14174,410

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

DRHP

Credit ratings

Concalls